CD274 and cancer: In addition to demonstrating the role of baseline levels of circulating PD-L1+ T cells in ICI-mediated cancer treatments, assessing the levels of circulating PD-L1+ T cells after patients are treated with anti-PD-(L)1 immunotherapy has emerged as a new approach to investigate the underlying mechanism and biomarker potential of these molecular markers.